Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Obesity & metabolic patent intelligence

GLP-1, GIP/GLP-1, diabetes, and metabolic disease patents — critical for obesity market IP tracking.

Patents
284

Quick answer

284 US pharmaceutical patents in our index match Obesity & metabolic title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 8563614

    Use of treprostinil to treat neuropathic diabetic foot ulcers

    United Therapeutics Corporation · Granted Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8541475

    MAO-B inhibitors useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8541456

    Roflumilast for the treatment of diabetes mellitus type 2

    TAKEDA GMBH · Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8492405

    Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity

    Takeda Pharmaceutical Company Limited · Granted Tue Jul 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8426597

    Nitrate derivatives of cilostazol for the treatment of vascular and metabolic diseases

    CARDIOLYNX AG · Granted Tue Apr 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8420612

    Diabetes treatment methods and drug targets therefor

    The Regents of the University of California · Granted Tue Apr 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8404869

    Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome

    MAZENCE INC. · Granted Tue Mar 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8383580

    Methods of administering lipocalins to treat metabolic disorders and cardiovascular diseases

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8334282

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Dec 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8318666

    Use of leptin to treat metabolic abnormalities associated with lipoatrophy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 27 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8309525

    Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof

    The Regents of the University of California · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8293869

    Polymer conjugates of GLP-1

    Nektar Therapeutics · Granted Tue Oct 23 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8278272

    GLP-1, exendin-4, peptide analogs and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 02 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8263662

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    The Regents of the University of California · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8263759

    Sets of probes and primers for the diagnosis of select cancers

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8236821

    Substituted N-phenyl-5-phenyl-pyrazolin-3-yl amides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Aug 07 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8217038

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Jul 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8158677

    Treatment of viral infections by modulation of host cell metabolic pathways

    THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Tue Apr 17 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8138216

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Mar 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8133904

    Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Mar 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8129341

    Methods for treating diabetic wounds

    CALREGEN INC. · Granted Tue Mar 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8124802

    MAO inhibiting N-benzyl-N-propargyl-amines useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Feb 28 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 23 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8101740

    Positron emission tomography probes for imaging immune activation and selected cancers

    The Regents of the University of California · Granted Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8088926

    Substituted 2-methyl-2-phenoxy-N-propyl-propionamides as cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Jan 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8088798

    Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jensen Discovery, Inc. · Granted Tue Jan 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8088809

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Jan 03 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8084016

    Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolitic products

    The Regents of the University of California · Granted Tue Dec 27 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8067416

    Methods and compositions for the treatment of metabolic disorders

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Nov 29 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7998968

    Substituted pyrimidines and [1,2, 4] triazoles and the use thereof for treating prophylaxis, cardiovascular diseases, metabolic diseases and/or central nervous system diseases

    Takeda Pharmaceutical Company Limited · Granted Tue Aug 16 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7998928

    Method of treatment of type-1 diabetes with a humanin analogue

    The Regents of the University of California · Granted Tue Aug 16 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7994143

    Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates

    The Regents of the University of California · Granted Tue Aug 09 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7994226

    Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products

    The Regents of the University of California · Granted Tue Aug 09 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7956220

    MAO-B inhibitors useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Jun 07 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7932289

    Remedy for diabetes

    Takeda Pharmaceutical Company Limited · Granted Tue Apr 26 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 21 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7906482

    Anti-obesity agents

    Advanced Diagnostics and Discovery · Granted Tue Mar 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7888116

    Uses of notch receptors, notch ligands, and notch modulators in methods related to metabolic diseases

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Feb 15 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7879909

    Use of Treprostinil to treat neuropathic diabetic foot ulcers

    United Therapeutics Corporation · Granted Tue Feb 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7803940

    Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 28 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7759335

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrm Discovery, Inc. · Granted Tue Jul 20 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7749983

    Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates

    The Regents of the University of California · Granted Tue Jul 06 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7718386

    Methods for the diagnosis of diabetes

    The Regents of the University of California · Granted Tue May 18 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 13 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7687481

    Cannabinoid receptor antagonists/inverse agonists useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Mar 30 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 25 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7666889

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Feb 23 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7662780

    Administering hypocretin to obese individuals

    The Regents of the University of California · Granted Tue Feb 16 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7655685

    Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

    Jenrin Discovery, LLC · Granted Tue Feb 02 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7651707

    Method for lowering blood pressure in pre-hypertensive individuals and/or individuals with metabolic syndrome

    The Regents of the University of California · Granted Tue Jan 26 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7651845

    Method and apparatus for glucose control and insulin dosing for diabetics

    The Regents of the University of California · Granted Tue Jan 26 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 21 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7649115

    MAO-B inhibitors useful for treating obesity

    Jenrin Discovery, LLC · Granted Tue Jan 19 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Obesity & metabolic patents are indexed?

284 patents match our Obesity & metabolic classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.